Literature DB >> 23383550

[Atypical location of Wegener's granulomatosis with breast involvement: case report].

Tacjana Barczyńska1, Iwona Dankiewicz-Fares, Halina Bilińska-Reszkowska, Joanna Zalewska, Sławomir Jeka.   

Abstract

INTRODUCTION: Wegener's granulomatosis is a disease of unknown etiology associated with the presence of serum antibodies against proteinase 3 in most cases. It is characterized by formation of inflammatory infiltrates presenting as granulomas with fibrinoid necrosis, as well as by ulceration and inflammation of small and medium-sized vessels with the involvement of upper and lower airways and kidneys. The process may also occur in other less typical locations, such as the gastrointestinal tract, heart, and nervous system. There are some reports on the location of lesions in the breast. CASE REPORT: We report a case of a 57-year-old female with Wegener's granulomatosis. In this patient, lesions in the skin, kidneys, upper airways, and lungs were accompanied by a breast tumor revealing the distinctive pattern of an inflammatory granuloma. The disease began in December 2002. The patient experienced painful and swollen joints, fever, mucous-purulent-bloody nasal discharge, and subcutaneous nodules with a tendency to ulceration. Histologically, the nodules had a texture typical for inflammatory granuloma. Renal symptoms included mild proteinuria, abnormalities in the sediment (fresh and leached erythrocytes), and slightly elevated serum creatinine. HRCT of the lungs revealed bilateral pulmonary nodules. The presence of antineutrophil cytoplasmic antibodies in serum with the cytoplasmic fluorescence pattern (c-ANCA/PR-3) was confirmed. The disease progressed with perforation of the nasal septum and extensive destructive changes within the bony structures of the paranasal sinuses. The patient underwent thoracic surgery in 2008 due to an inflammatory tumor in the upper lobe of the right lung. Two years later a tumor in the right breast was detected. Histopathology of the lung and breast tumors showed high similarity of both processes corresponding to lesions typical for Wegener's granulomatosis. The patient was treated with prednisone, methylprednisolone, methotrexate, cyclophosphamide, and azathioprine.
CONCLUSIONS: This case provides evidence that Wegener's granulomatosis is a systemic disease with a wide spectrum of organ involvement which should be taken into account during differential diagnosis of breast tumors.

Entities:  

Mesh:

Year:  2011        PMID: 23383550

Source DB:  PubMed          Journal:  Ann Acad Med Stetin        ISSN: 1427-440X


  5 in total

1.  Breast Involvement in Anti-Neutrophil Cytoplasmic Antibodies Positive Granulomatosis With Polyangiitis in a 64-Year-Old Female Patient.

Authors:  Monika Ryba; Andrzej Konieczny; Zbigniew Hruby
Journal:  Arch Rheumatol       Date:  2017-04-13       Impact factor: 1.472

2.  Mastitis associated with Sjögren's syndrome: a series of nine cases.

Authors:  Radjiv Goulabchand; Assia Hafidi; Ingrid Millet; Jacques Morel; Cédric Lukas; Sébastien Humbert; Sophie Rivière; Christian Gény; Christian Jorgensen; Alain Le Quellec; Hélène Perrochia; Philippe Guilpain
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

3.  Blindness in a Sri Lankan woman with bilateral breast lumps: a case report.

Authors:  Vipula R Bataduwaarachchi; Rukshani Galappaththi; Nirmali Tissera
Journal:  J Med Case Rep       Date:  2015-12-29

4.  Bilateral facial palsy in rapidly progressive course of Wegener's granulomatosis: a case report.

Authors:  Anna Roszkowska; Monika Morawska-Kochman; Hanna Temporale; Małgorzata Sikorska-Żuk; Tomasz Kręcicki
Journal:  Case Rep Otolaryngol       Date:  2013-09-25

Review 5.  Mastitis in Autoimmune Diseases: Review of the Literature, Diagnostic Pathway, and Pathophysiological Key Players.

Authors:  Radjiv Goulabchand; Assia Hafidi; Philippe Van de Perre; Ingrid Millet; Alexandre Thibault Jacques Maria; Jacques Morel; Alain Le Quellec; Hélène Perrochia; Philippe Guilpain
Journal:  J Clin Med       Date:  2020-03-30       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.